Humacyte, Inc. HUMA
Regular-session close
After hours · Nov 19, 4:00 PM ET
- YTD
- -43.55%
- 1 year
- -53.63%
5D -0.0627 (-10.36%)
- Market cap
- 150.71M
- EPS (ttm)
- -0.45
- Shares out
- 128.67M
- Forward P/E
- -5.41
- YTD return
- -43.55%
- 1-year return
- -53.63%
- 50-day average
- 4.85
- 200-day average
- 5.43
- Enterprise value
- 580.94M
- Volume
- 3.74M
- Avg volume
- 5.46M
- Open
- 0.5194
- Previous close
- 0.50
- Day's range
- 0.5157 – 0.5799
- 52-week range
- 0.337 – 1.53
- Beta
- 1.47
- Analysts
- Strong Buy
- Price target
- 13.71 (+2428.0%)
Key statistics
- Free cash flow
- -58.33M
- Total cash
- 20.57M
- Total debt
- 17.52M
- Short % of float
- 20.36%
Fundamental scorecard
6 of 25 checks passed on HUMA’s reported financials
6of 25 checks passed
- Value 2 of 5
- Growth 2 of 5
- Profitability 0 of 5
- Financial health 2 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 8, 2024 | Sep 1, 2024 | -0.26 | -0.33 | -0.07 | -26.92% |
| Aug 13, 2024 | Jun 1, 2024 | -0.23 | — | — | — |
| Aug 13, 2024 | Jun 1, 2024 | -0.23 | -0.27 | -0.04 | -17.39% |
| May 10, 2024 | Mar 1, 2024 | -0.23 | — | — | — |
| May 10, 2024 | Mar 1, 2024 | -0.23 | -0.29 | -0.06 | -26.09% |
| Mar 22, 2024 | Dec 1, 2023 | -0.25 | -0.24 | +0.01 | +4.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2024 | Benchmark | main | Buy | Buy |
| Dec 20, 2024 | D. Boral Capital | main | Buy | Buy |
| Dec 20, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 21, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 18, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Humacyte, Inc.
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- humacyte.com
News
Humacyte Submits sBLA To FDA For Acellular Tissue Engineered Vessel Seeking Approval In Arteriovenous Access For Hemodialysis In Patients With End-Stage Kidney Disease
Humacyte Submits Supplemental Biologics License Application to FDA for the Acellular Tissue Engineered Vessel in Dialysis Access
Humacyte Presents Long-Term Clinical Data Demonstrating Low Atherosclerosis Susceptibility in Acellular Tissue Engineered Vessel
Humacyte Q3 Earnings Call Highlights Barclays Maintains Equal-Weight on Humacyte, Raises Price Target to $0.6
12 Health Care Stocks Moving In Tuesday's Intraday Session
Humacyte Q3 2026 Earnings Call Transcript Humacyte Q3 EPS $(0.06) Beats $(0.08) Estimate, Sales $1.028M Beat $766.000K Estimate
Humacyte Announces Three Presentations At American Heart Association Scientific Sessions, November 6–9; Two Additional Presentations To Cover First-In-Human Phase 2a Study Design And Preclinical Results For Its Investigational Coronary Tissue Engineered Vessel
Humacyte Presents Interim Results From V012 Phase 3 Clinical Trial Of Acellular Tissue Engineered Vessel In Arteriovenous Access For Female Hemodialysis Patients, At ASN Kidney Week 2026
Your note
Sign in to keep a note on HUMA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AYABUDGE, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Aug 20, 2023 | 8,191,140 |
| BINDER GORDON M | Director | Purchase | May 14, 2024 | 0 |
| CONSTANTINO MICHAEL T | Director | Purchase | Dec 3, 2024 | 16,950 |
| DOUGAN BRADY W | Director | Sale | Nov 19, 2024 | 0 |
| GREEN CHARLES BRUCE | Director | Conversion of Exercise of derivative security | Sep 12, 2024 | 2,400 |
| NIKLASON LAURA E | Chief Executive Officer | Sale | Nov 19, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 5.99% | 7,539,339 | 35.06M | Sep 29, 2024 |
| Vanguard Group Inc | 4.02% | 5,058,689 | 23.52M | Sep 29, 2024 |
| State Street Corporation | 3.79% | 4,764,155 | 22.15M | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.62% | 2,040,218 | 9.49M | Sep 29, 2024 |
| Millennium Management Llc | 1.01% | 1,267,507 | 5.89M | Sep 29, 2024 |
| Voloridge Investment Management, LLC | 1.00% | 1,259,940 | 5.86M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.26% | 2,839,095 | 13.20M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 2.06% | 2,592,815 | 12.06M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.83% | 2,306,743 | 10.73M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.98% | 1,232,203 | 5.73M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.71% | 899,704 | 4.18M | Aug 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.63% | 789,389 | 3.67M | Oct 30, 2024 |
